Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 22

Trial Status

Completed2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT02657928Phase 2Completed
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Estrogen Receptor PositivePostmenopausalRecurrent Fallopian Tube Carcinoma+3 more
PrincipalinvestigatorStart date: 2016-07-08
NCT02283658Phase 2Completed
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Ovarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous Cystadenocarcinoma+6 more
PrincipalinvestigatorStart date: 2014-11-14

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Russell Schilder

Gynecologic Oncology Group

Related
5 trials

Shared therapeutic areas:

Ovarian Endometrioid AdenocarcinomaOvarian Serous CystadenocarcinomaRecurrent Fallopian Tube Carcinoma+3 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score15%

Emese Zsiros

Roswell Park Cancer Institute

Related
6 trials

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score13%

Evanthia Galanis, MD

Mayo Clinic

Related
5 trials

Shared therapeutic areas:

Ovarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaRecurrent Fallopian Tube Carcinoma+2 more

Worked with same sponsors:

Mayo ClinicNational Cancer Institute (NCI)
Similarity Score13%

Kunle Odunsi

Roswell Park Cancer Institute

Related
5 trials

Shared therapeutic areas:

Recurrent Ovarian CarcinomaEstrogen Receptor PositiveRecurrent Fallopian Tube Carcinoma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score13%

Shannon N Westin

M.D. Anderson Cancer Center

Related
7 trials

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Shannon Westin

M.D. Anderson Cancer Center

Related
5 trials

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Lilie L Lin

M.D. Anderson Cancer Center

Related
5 trials

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Amir A Jazaeri

M.D. Anderson Cancer Center

Related
7 trials

Shared therapeutic areas:

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Lupe Salazar

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
6 trials

Shared therapeutic areas:

Ovarian Endometrioid AdenocarcinomaOvarian Serous Cystadenocarcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score5%

Banu Arun

M.D. Anderson Cancer Center

Related
5 trials

Shared therapeutic areas:

Estrogen Receptor PositivePostmenopausal

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT02657928Phase 2PrincipalInvestigator

Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Estrogen Receptor PositivePostmenopausalRecurrent Fallopian Tube Carcinoma+3 more
Completed
NCT02283658Phase 2PrincipalInvestigator

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous Cystadenocarcinoma+6 more
Completed

All 2 trials loaded